Impact of visceral metastases on outcome to abiraterone after docetaxel in castration-resistant prostate cancer patients

The objective of this study was to analyze the impact of visceral metastases in castration-resistant prostate cancer (CRPC) treated with abiraterone.

All CRPC patients received abiraterone 1000 mg daily plus prednisone 10 mg orally daily.

Liver and lung metastases were considered as visceral metastases.

Of 265 CRPC patients, 49 had visceral metastases. Results on progression-free survival were not significantly different in patients with or without visceral metastases. Conversely, the median overall survival between the two groups was 12. 4 and 18. 5 months (p = 0. 01), respectively, and median overall survival of patients with liver-only disease versus other sites was 10. 5 versus 18. 5 months (p = 0. 006), respectively.

Visceral disease appears to be an important predictor of clinical outcome in CRPC patients treated with abiraterone.

Future oncology (London, England). 2015 Oct 05 [Epub ahead of print]

Vincenza Conteduca, Orazio Caffo, Lucia Fratino, Giovanni Lo Re, Umberto Basso, Alessandro D'Angelo, Maddalena Donini, Francesco Verderame, Raffaele Ratta, Giuseppe Procopio, Enrico Campadelli, Francesco Massari, Donatello Gasparro, Paola Ermacora, Caterina Messina, Monica Giordano, Daniele Alesini, Vittorina Zagonel, Antonello Veccia, Cristian Lolli, Francesca Maines, Ugo De Giorgi

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy. , Santa Chiara Hospital, Trento, Italy. , National Cancer Center CRO, Aviano, Italy. , Santa Maria Degli Angeli General Hospital, Pordenone, Italy. , Medical Oncology Unit I, Department of Clinical & Experimental Oncology Istituto Oncologico Veneto IOV, IRCCS, Padova, Italy. , S Vincenzo Hospital, Taormina, Italy. , Istituti Ospitalieri di Cremona, Cremona, Italy. , Medical Oncology, Azienda Ospedaliera Villa Sofia-Cervello, Palermo, Italy. , Campus Bio-Medico University of Rome, Rome, Italy. , Oncology Unit I, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy. , Civil Hospital, Lugo di Romagna, Italy. , Institut Gustave Roussy, Villejuif, France. , University Hospital of Parma, Parma, Italy. , Dipartimento di Oncologia, Azienda Ospedaliero-Universitaria, Udine, Italy. , Medical Oncology Unit, Piazza OMS, 1, Pope John Paul XXIII Hospital, Bergamo, Italy. , Santa Anna Hospital, Como, Italy. , Division of Medical Oncology, Università la Sapienza Roma, Rome, Italy. , Medical Oncology Unit I, Department of Clinical & Experimental Oncology Istituto Oncologico Veneto IOV, IRCCS, Padova, Italy. , Santa Chiara Hospital, Trento, Italy. , Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy. , Santa Chiara Hospital, Trento, Italy. , Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.

PubMed

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe